China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically ...

Among the more than 100 types of human papillomavirus (HPV), at least 14 are considered as 'high-risk' types which can cause ...

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...

MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.

Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...

The Centers for Disease Control and Prevention (CDC) started recommending the HPV vaccine, which protects against the nine ...

Starting Monday, the Estonian Health Insurance Fund (EHIF) will begin sending SMS reminders to parents of children in the ...

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory ...

Merck & Co., Inc. (NYSE: MRK) is one of the. The company announced that the US FDA approved ENFLONSIA™ (clesrovimab-cfor) for ...

On Monday, plaintiffs’ lawyers filed their opening brief asking the U.S. Court of Appeals for the Fourth Circuit to reinstate ...

Biological E partners with China’s Recbio to produce REC603 a 9-valent HPV vaccine in India The collaboration aims to expand ...

Vaccine businesses seen as valuable parts of pharma groups but government hostility could deter future developments ...